|1.||Tindall, Donald J: 3 articles (12/2009 - 11/2004)|
|2.||Schmidt, Lucy J: 3 articles (12/2009 - 11/2004)|
|3.||Hartmann, R W: 3 articles (11/2000 - 05/2000)|
|4.||Tsuboi, Ryoji: 2 articles (03/2014 - 07/2004)|
|5.||Kawashima, Makoto: 2 articles (03/2014 - 07/2004)|
|6.||Ballman, Karla V: 2 articles (12/2009 - 07/2007)|
|7.||Arlt, Wiebke: 2 articles (09/2009 - 06/2003)|
|8.||Waldhäusl, W: 2 articles (07/2003 - 12/2001)|
|9.||Nowotny, P: 2 articles (07/2003 - 12/2001)|
|10.||Vierhapper, H: 2 articles (07/2003 - 12/2001)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/01/1991 - "Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia."
03/01/2007 - "Medline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. "
01/01/2005 - "3) a 5 alpha-reductase inhibitor has greatly alleviated the symptoms associated with benign prostatic hyperplasia. "
02/01/2003 - "Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia."
01/01/2002 - "Tested for inhibition of human 5 alpha-reductase 1 and 2--a target for the treatment of benign prostatic hyperplasia (BPH)--the title compounds showed some inhibitory activity."
01/01/2009 - "Serenoa repens is one among the many naturally occurring 5 alpha reductase (5aR) inhibitors which has gained popularity as a magical remedy for androgenetic alopecia. "
07/01/1987 - "We used a primate model of male-pattern baldness to test the efficacy of a topically applied 5 alpha-reductase inhibitor and antiandrogen (4-MA) in the prevention of baldness. "
06/01/2001 - "Recent studies suggest that 5 alpha-reductase type 2 (5 alpha R2) rather than 5 alpha R1 plays a key role in the pathogenesis of male-pattern baldness. "
07/01/2003 - "These results are compatible with the idea that 5 alpha-reductase inhibition is of no therapeutical value in female-pattern baldness."
12/01/2001 - "In the majority of men with male pattern baldness endogenous production of DHT is markedly increased, providing a rationale for therapeutic 5 alpha-reductase inhibition in this disorder."
|3.||Prostatic Neoplasms (Prostate Cancer)
09/01/2012 - "Two randomised trials and negative conclusion of the FDA about inhibitors of 5 alpha-reductase in prevention of prostate cancer need a revision of the indications of these drugs. "
01/01/1997 - "Consequently, the odds ratios may be underestimated and the study, although negative, cannot exclude the previously hypothesized possibility that a positive relationship between intraprostatic 5 alpha-reductase activity and prostate cancer may exist. "
06/01/2005 - "We here investigate 5 alpha-reductase inhibition assays in vitro to measure the effect of incubation time on the apparent inhibition constant (Ki) for both constitutional and somatic (prostate cancer) enzyme variants. "
11/01/2002 - "Furthermore, 5 alpha-reductase which catalyze the conversion of T to DHT, has been a target of manipulation in the treatment of prostatic cancer, hence synthetic 5 alpha-reductase activity inhibitors have shown therapeutic promise. "
03/01/1997 - "A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis."
05/01/1986 - "Unfortunately, until very recently, the lack of a suitable 5 alpha-reductase inhibitor made it very difficult to adequately test the hypothesis that such an inhibitor might be useful in the treatment of hirsutism and certain other androgen-related diseases. "
11/01/1998 - "These data demonstrate that 5 alpha-reductase inhibition may be an effective treatment in women suffering from idiopathic hirsutism. "
12/12/1997 - "Diagnostic advantages might have been expected in patients with idiopathic hirsutism, in whom increased 5 alpha-reductase activity may be reflected by this parameter. "
01/01/1996 - "Therefore, our findings do not support the concept of increased 5 alpha-reductase activity in all patients with idiopathic hirsutism."
01/01/1995 - "Enhanced 5 alpha-reductase activity has been found in the skin of the majority of women with hirsutism. "
07/01/1995 - "In a previous study a reduced proliferation rate of androgen responsive R3327-H tumor was demonstrated after in vivo treatment with 17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA) - a putative 5 alpha-reductase inhibitor. "
04/01/1996 - "Comparisons were based on pH profiles and sensitivities to selective inhibitors of 5 alpha-reductase In the cancer lines, activity was greatest over the pH range 7-8, compared to a sharp peak of activity between pH 5-5.5 in BPH tissue and COS cells expressing 5 alpha R2. "
01/01/1992 - "Such reduction in tissue DHT, secondary to inhibition of the tissue 5 alpha-reductase enzyme, appears to be more difficult to achieve in tumors than in the normal prostate. "
02/01/1991 - "If the tumor is dependent only on DHT for neoplastic growth, the unique characteristics of a 5 alpha-reductase inhibitor offer several potential actions that warrant a systematic evaluation."
01/01/1987 - "The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice."
|6.||Neurotransmitter Agents (Neurotransmitter)
|7.||GABA-A Receptors (GABA(A) Receptor)
|9.||gamma-Aminobutyric Acid (GABA)
|1.||Skin Transplantation (Skin Grafting)
|4.||Drug Therapy (Chemotherapy)